Details of the Drug

General Information of Drug (ID: DMN9RPO)

Drug Name

Nafcillin

Synonyms

Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Arthritis	FA20	Approved	[1]
Staphylococcal pneumonia	N.A.	Approved	[2]
Staphylococcus aureus infection	N.A.	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antibiotics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

414.5

Logarithm of the Partition Coefficient (xlogp)

2.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 30 mg/L []
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 5 min []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 3.3 mL/min/kg [4]
Elimination: 27% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 33 - 61 minutes [4]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 188.5986 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.13% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.22 L/kg [4]

Chemical Identifiers

Formula: C21H22N2O5S
IUPAC Name: (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Canonical SMILES: CCOC1=C(C2=CC=CC=C2C=C1)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
InChI: InChI=1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1
InChIKey: GPXLMGHLHQJAGZ-JTDSTZFVSA-N

Cross-matching ID

PubChem CID: 8982
ChEBI ID: CHEBI:7447
CAS Number: 147-52-4
DrugBank ID: DB00607
TTD ID: D0A0JH
VARIDT ID: DR01384
ACDINA ID: D01266

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Penicillin binding protein (Bact PBP)	TTJP4SM	NOUNIPROTAC	Binder	[6]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[8]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[9]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Gene/Protein Processing	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nafcillin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Upadacitinib	DM32B5U	Moderate	Increased metabolism of Nafcillin caused by Upadacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[11]
Tofacitinib	DMBS370	Moderate	Increased metabolism of Nafcillin caused by Tofacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[12]
-----------

Coadministration of a Drug Treating the Disease Different from Nafcillin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Midostaurin	DMI6E0R	Moderate	Increased metabolism of Nafcillin caused by Midostaurin mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[13]
Gilteritinib	DMTI0ZO	Moderate	Accelerated clearance of Nafcillin due to the transporter induction by Gilteritinib.	Acute myeloid leukaemia [2A60]	[14]
Oliceridine	DM6MDCF	Major	Increased metabolism of Nafcillin caused by Oliceridine mediated induction of CYP450 enzyme.	Acute pain [MG31]	[15]
Donepezil	DMIYG7Z	Moderate	Increased metabolism of Nafcillin caused by Donepezil mediated induction of CYP450 enzyme.	Alzheimer disease [8A20]	[16]
Ivabradine	DM0L594	Moderate	Increased metabolism of Nafcillin caused by Ivabradine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[17]
Dronedarone	DMA8FS5	Moderate	Increased metabolism of Nafcillin caused by Dronedarone mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[18]
Nifedipine	DMSVOZT	Moderate	Increased metabolism of Nafcillin caused by Nifedipine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[19]
Bedaquiline	DM3906J	Major	Increased metabolism of Nafcillin caused by Bedaquiline mediated induction of CYP450 enzyme.	Antimicrobial drug resistance [MG50-MG52]	[17]
Telithromycin	DMZ4P3A	Moderate	Increased metabolism of Nafcillin caused by Telithromycin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Cariprazine	DMJYDVK	Moderate	Increased metabolism of Nafcillin caused by Cariprazine mediated induction of CYP450 enzyme.	Bipolar disorder [6A60]	[21]
Erdafitinib	DMI782S	Major	Increased metabolism of Nafcillin caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[22]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Nafcillin caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[23]
Ixabepilone	DM2OZ3G	Moderate	Increased metabolism of Nafcillin caused by Ixabepilone mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[24]
Lapatinib	DM3BH1Y	Moderate	Increased metabolism of Nafcillin caused by Lapatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
HKI-272	DM6QOVN	Major	Increased metabolism of Nafcillin caused by HKI-272 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
LY2835219	DM93VBZ	Moderate	Increased metabolism of Nafcillin caused by LY2835219 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[25]
Exemestane	DM9HPW3	Moderate	Increased metabolism of Nafcillin caused by Exemestane mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[26]
Esterified estrogens	DM9KZDO	Moderate	Increased metabolism of Nafcillin caused by Esterified estrogens mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Tucatinib	DMBESUA	Moderate	Increased metabolism of Nafcillin caused by Tucatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Palbociclib	DMD7L94	Moderate	Increased metabolism of Nafcillin caused by Palbociclib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Quinestrol	DMJ6H1Z	Moderate	Increased metabolism of Nafcillin caused by Quinestrol mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Tamoxifen	DMLB0EZ	Moderate	Increased metabolism of Nafcillin caused by Tamoxifen mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[29]
Cabazitaxel	DMPAZHC	Moderate	Increased metabolism of Nafcillin caused by Cabazitaxel mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[30]
Bosutinib	DMTI8YE	Major	Increased metabolism of Nafcillin caused by Bosutinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[31]
Estradiol	DMUNTE3	Moderate	Increased metabolism of Nafcillin caused by Estradiol mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Atorvastatin	DMF28YC	Moderate	Increased metabolism of Nafcillin caused by Atorvastatin mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[32]
Macitentan	DMP79A1	Moderate	Increased metabolism of Nafcillin caused by Macitentan mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[33]
PF-04449913	DMSB068	Major	Increased metabolism of Nafcillin caused by PF-04449913 mediated induction of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[34]
Dihydrocodeine	DMB0FWL	Moderate	Increased metabolism of Nafcillin caused by Dihydrocodeine mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[35]
Irinotecan	DMP6SC2	Moderate	Increased metabolism of Nafcillin caused by Irinotecan mediated induction of CYP450 enzyme.	Colorectal cancer [2B91]	[36]
Drospirenone	DM1A9W3	Moderate	Increased metabolism of Nafcillin caused by Drospirenone mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[27]
Levonorgestrel	DM1DP7T	Moderate	Increased metabolism of Nafcillin caused by Levonorgestrel mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[27]
Levobupivacaine	DM783CH	Minor	Increased metabolism of Nafcillin caused by Levobupivacaine mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[37]
Alfentanil	DMVO0UB	Moderate	Increased metabolism of Nafcillin caused by Alfentanil mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[38]
Mycophenolic acid	DMRBMAU	Moderate	Altered absorption of Nafcillin due to GI flora changes caused by Mycophenolic acid.	Crohn disease [DD70]	[39]
Mifepristone	DMGZQEF	Moderate	Increased metabolism of Nafcillin caused by Mifepristone mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[40]
Osilodrostat	DMIJC9X	Moderate	Increased metabolism of Nafcillin caused by Osilodrostat mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[41]
Ivacaftor	DMZC1HS	Moderate	Increased metabolism of Nafcillin caused by Ivacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[42]
MK-8228	DMOB58Q	Moderate	Accelerated clearance of Nafcillin due to the transporter induction by MK-8228.	Cytomegaloviral disease [1D82]	[12]
Rivaroxaban	DMQMBZ1	Moderate	Increased metabolism of Nafcillin caused by Rivaroxaban mediated induction of CYP450 enzyme.	Deep vein thrombosis [BD71]	[43]
Aprepitant	DM053KT	Moderate	Increased metabolism of Nafcillin caused by Aprepitant mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[44]
Vilazodone	DM4LECQ	Moderate	Increased metabolism of Nafcillin caused by Vilazodone mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[45]
Vortioxetine	DM6F1PU	Moderate	Increased metabolism of Nafcillin caused by Vortioxetine mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[46]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Increased metabolism of Nafcillin caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme.	Discovery agent [N.A.]	[47]
Zonisamide	DM0DTF7	Moderate	Increased metabolism of Nafcillin caused by Zonisamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Stiripentol	DMMSDOY	Moderate	Increased metabolism of Nafcillin caused by Stiripentol mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Nicardipine	DMCDYW7	Moderate	Increased metabolism of Nafcillin caused by Nicardipine mediated induction of CYP450 enzyme.	Essential hypertension [BA00]	[19]
Praziquantel	DMOU1PK	Moderate	Increased metabolism of Nafcillin caused by Praziquantel mediated induction of CYP450 enzyme.	Flatworm infection [1F70-1F86]	[49]
Bay 80-6946	DMLOS5R	Moderate	Accelerated clearance of Nafcillin due to the transporter induction by Bay 80-6946.	Follicular lymphoma [2A80]	[50]
Tazemetostat	DMWP1BH	Major	Increased metabolism of Nafcillin caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[51]
Solifenacin	DMG592Q	Moderate	Increased metabolism of Nafcillin caused by Solifenacin mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[52]
Mirabegron	DMS1GYT	Minor	Increased metabolism of Nafcillin caused by Mirabegron mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[53]
Ripretinib	DM958QB	Moderate	Increased metabolism of Nafcillin caused by Ripretinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[12]
Sunitinib	DMCBJSR	Moderate	Increased metabolism of Nafcillin caused by Sunitinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[12]
Avapritinib	DMK2GZX	Major	Increased metabolism of Nafcillin caused by Avapritinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[17]
Ergotamine	DMKR3C5	Moderate	Increased metabolism of Nafcillin caused by Ergotamine mediated induction of CYP450 enzyme.	Headache [8A80-8A84]	[12]
Daclatasvir	DMSFK9V	Major	Increased metabolism of Nafcillin caused by Daclatasvir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[17]
Pretomanid	DMDYA31	Major	Increased metabolism of Nafcillin caused by Pretomanid mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[54]
MK-1439	DM215WE	Major	Increased metabolism of Nafcillin caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Delavirdine	DM3NF5G	Moderate	Increased metabolism of Nafcillin caused by Delavirdine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Fosamprenavir	DM4W9B3	Moderate	Increased metabolism of Nafcillin caused by Fosamprenavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Fostemsavir	DM50ILT	Minor	Increased metabolism of Nafcillin caused by Fostemsavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Cobicistat	DM6L4H2	Moderate	Increased metabolism of Nafcillin caused by Cobicistat mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Tipranavir	DM8HJX6	Moderate	Increased metabolism of Nafcillin caused by Tipranavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Dolutegravir	DMCZGRE	Minor	Increased metabolism of Nafcillin caused by Dolutegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Saquinavir	DMG814N	Moderate	Increased metabolism of Nafcillin caused by Saquinavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Elvitegravir	DMG9B1U	Moderate	Increased metabolism of Nafcillin caused by Elvitegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Nafcillin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[59]
Rilpivirine	DMJ0QOW	Moderate	Increased metabolism of Nafcillin caused by Rilpivirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Amprenavir	DMLMXE0	Moderate	Increased metabolism of Nafcillin caused by Amprenavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Atazanavir	DMSYRBX	Moderate	Increased metabolism of Nafcillin caused by Atazanavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Maraviroc	DMTL94F	Moderate	Accelerated clearance of Nafcillin due to the transporter induction by Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Verapamil	DMA7PEW	Moderate	Increased metabolism of Nafcillin caused by Verapamil mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[19]
Felodipine	DMOSW35	Moderate	Increased metabolism of Nafcillin caused by Felodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[19]
Tolvaptan	DMIWFRL	Moderate	Increased metabolism of Nafcillin caused by Tolvaptan mediated induction of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[17]
Probenecid	DMMFWOJ	Minor	Decreased elimination of Nafcillin caused by Probenecid mediated competitive inhibition of renal tubular secretion.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[60]
Suvorexant	DM0E6S3	Moderate	Increased metabolism of Nafcillin caused by Suvorexant mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[61]
Ramelteon	DM7IW9J	Moderate	Increased metabolism of Nafcillin caused by Ramelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[62]
Tasimelteon	DMLOQ1V	Moderate	Increased metabolism of Nafcillin caused by Tasimelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[63]
ITI-007	DMUQ1DO	Major	Increased metabolism of Nafcillin caused by ITI-007 mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[64]
Naloxegol	DML0B41	Moderate	Increased metabolism of Nafcillin caused by Naloxegol mediated induction of CYP450 enzyme.	Large intestine motility disorder [DB32]	[65]
Pemigatinib	DM819JF	Major	Increased metabolism of Nafcillin caused by Pemigatinib mediated induction of CYP450 enzyme.	Liver cancer [2C12]	[17]
Crizotinib	DM4F29C	Moderate	Increased metabolism of Nafcillin caused by Crizotinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[66]
Brigatinib	DM7W94S	Major	Increased metabolism of Nafcillin caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[12]
Ceritinib	DMB920Z	Moderate	Increased metabolism of Nafcillin caused by Ceritinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[67]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Nafcillin caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[68]
PF-06463922	DMKM7EW	Major	Increased metabolism of Nafcillin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[69]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Nafcillin caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[70]
Pralsetinib	DMWU0I2	Moderate	Increased metabolism of Nafcillin caused by Pralsetinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[71]
Capmatinib	DMYCXKL	Major	Increased metabolism of Nafcillin caused by Capmatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[72]
Selpercatinib	DMZR15V	Major	Increased metabolism of Nafcillin caused by Selpercatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[17]
Artemether	DM48QOT	Moderate	Increased metabolism of Nafcillin caused by Artemether mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[12]
Idelalisib	DM602WT	Moderate	Increased metabolism of Nafcillin caused by Idelalisib mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[73]
IPI-145	DMWA24P	Moderate	Increased metabolism of Nafcillin caused by IPI-145 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[74]
Acalabrutinib	DM7GCVW	Moderate	Increased metabolism of Nafcillin caused by Acalabrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[75]
Ibrutinib	DMHZCPO	Moderate	Increased metabolism of Nafcillin caused by Ibrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[76]
Ponatinib	DMYGJQO	Moderate	Increased metabolism of Nafcillin caused by Ponatinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[12]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Nafcillin caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[77]
Selumetinib	DMC7W6R	Major	Increased metabolism of Nafcillin caused by Selumetinib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[78]
LGX818	DMNQXV8	Major	Increased metabolism of Nafcillin caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[79]
Estrone	DM5T6US	Moderate	Increased metabolism of Nafcillin caused by Estrone mediated induction of CYP450 enzyme.	Menopausal disorder [GA30]	[27]
Ethinyl estradiol	DMODJ40	Moderate	Increased metabolism of Nafcillin caused by Ethinyl estradiol mediated induction of CYP450 enzyme.	Menopausal disorder [GA30]	[47]
Rimegepant	DMHOAUG	Major	Increased metabolism of Nafcillin caused by Rimegepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[80]
Flibanserin	DM70DTN	Moderate	Increased metabolism of Nafcillin caused by Flibanserin mediated induction of CYP450 enzyme.	Mood disorder [6A60-6E23]	[81]
Panobinostat	DM58WKG	Moderate	Increased metabolism of Nafcillin caused by Panobinostat mediated induction of CYP450 enzyme.	Multiple myeloma [2A83]	[82]
Siponimod	DM2R86O	Major	Increased metabolism of Nafcillin caused by Siponimod mediated induction of CYP450 enzyme.	Multiple sclerosis [8A40]	[12]
Deflazacort	DMV0RNS	Major	Increased metabolism of Nafcillin caused by Deflazacort mediated induction of CYP450 enzyme.	Muscular dystrophy [8C70]	[17]
Fedratinib	DM4ZBK6	Major	Increased metabolism of Nafcillin caused by Fedratinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[17]
Nilotinib	DM7HXWT	Moderate	Increased metabolism of Nafcillin caused by Nilotinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[83]
Ruxolitinib	DM7Q98D	Moderate	Increased metabolism of Nafcillin caused by Ruxolitinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[84]
Imatinib	DM7RJXL	Moderate	Increased metabolism of Nafcillin caused by Imatinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[85]
Dasatinib	DMJV2EK	Moderate	Increased metabolism of Nafcillin caused by Dasatinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[12]
Modafinil	DMYILBE	Moderate	Increased metabolism of Nafcillin caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[86]
Rolapitant	DM8XP26	Moderate	Increased metabolism of Nafcillin caused by Rolapitant mediated induction of CYP450 enzyme.	Nausea/vomiting [MD90]	[87]
Entrectinib	DMMPTLH	Major	Increased metabolism of Nafcillin caused by Entrectinib mediated induction of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[88]
Levomethadyl Acetate	DM06HG5	Major	Increased metabolism of Nafcillin caused by Levomethadyl Acetate mediated induction of CYP450 enzyme.	Opioid use disorder [6C43]	[89]
S-297995	DM26IH8	Moderate	Increased metabolism of Nafcillin caused by S-297995 mediated induction of CYP450 enzyme.	Opioid use disorder [6C43]	[17]
Olaparib	DM8QB1D	Major	Increased metabolism of Nafcillin caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[12]
Butorphanol	DM5KYPJ	Major	Increased metabolism of Nafcillin caused by Butorphanol mediated induction of CYP450 enzyme.	Pain [MG30-MG3Z]	[15]
Buprenorphine	DMPRI8G	Moderate	Increased metabolism of Nafcillin caused by Buprenorphine mediated induction of CYP450 enzyme.	Pain [MG30-MG3Z]	[90]
Hydrocodone	DMQ2JO5	Major	Increased metabolism of Nafcillin caused by Hydrocodone mediated induction of CYP450 enzyme.	Pain [MG30-MG3Z]	[15]
Istradefylline	DM20VSK	Moderate	Increased metabolism of Nafcillin caused by Istradefylline mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[91]
Pimavanserin	DMR7IVC	Moderate	Increased metabolism of Nafcillin caused by Pimavanserin mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[92]
Macimorelin	DMQYJIR	Moderate	Increased metabolism of Nafcillin caused by Macimorelin mediated induction of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[93]
Lefamulin	DME6G97	Major	Accelerated clearance of Nafcillin due to the transporter induction by Lefamulin.	Pneumonia [CA40]	[94]
Ergonovine	DM0VEC1	Moderate	Increased metabolism of Nafcillin caused by Ergonovine mediated induction of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[12]
Lonafarnib	DMGM2Z6	Major	Increased metabolism of Nafcillin caused by Lonafarnib mediated induction of CYP450 enzyme.	Premature ageing appearance [LD2B]	[95]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Nafcillin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[96]
Darolutamide	DMV7YFT	Moderate	Increased metabolism of Nafcillin caused by Darolutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[97]
Silodosin	DMJSBT6	Moderate	Increased metabolism of Nafcillin caused by Silodosin mediated induction of CYP450 enzyme.	Prostate hyperplasia [GA90]	[12]
Apremilast	DMTWS9E	Moderate	Increased metabolism of Nafcillin caused by Apremilast mediated induction of CYP450 enzyme.	Psoriasis [EA90]	[98]
Riociguat	DMXBLMP	Moderate	Increased metabolism of Nafcillin caused by Riociguat mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[99]
Everolimus	DM8X2EH	Moderate	Accelerated clearance of Nafcillin due to the transporter induction by Everolimus.	Renal cell carcinoma [2C90]	[12]
Axitinib	DMGVH6N	Major	Increased metabolism of Nafcillin caused by Axitinib mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[100]
Temsirolimus	DMS104F	Moderate	Increased metabolism of Nafcillin caused by Temsirolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[12]
Quetiapine	DM1N62C	Moderate	Increased metabolism of Nafcillin caused by Quetiapine mediated induction of CYP450 enzyme.	Schizophrenia [6A20]	[12]
Aripiprazole	DM3NUMH	Moderate	Increased metabolism of Nafcillin caused by Aripiprazole mediated induction of CYP450 enzyme.	Schizophrenia [6A20]	[101]
Fentanyl	DM8WAHT	Major	Increased metabolism of Nafcillin caused by Fentanyl mediated induction of CYP450 enzyme.	Sensation disturbance [MB40]	[15]
Avanafil	DM75CXN	Moderate	Increased metabolism of Nafcillin caused by Avanafil mediated induction of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[102]
Tadalafil	DMJZHT1	Moderate	Increased metabolism of Nafcillin caused by Tadalafil mediated induction of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[17]
Voxelotor	DMCS6M5	Major	Increased metabolism of Nafcillin caused by Voxelotor mediated induction of CYP450 enzyme.	Sickle-cell disorder [3A51]	[103]
LDE225	DMM9F25	Major	Increased metabolism of Nafcillin caused by LDE225 mediated induction of CYP450 enzyme.	Skin cancer [2C30-2C37]	[104]
Larotrectinib	DM26CQR	Moderate	Accelerated clearance of Nafcillin due to the transporter induction by Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[12]
Docetaxel	DMDI269	Moderate	Increased metabolism of Nafcillin caused by Docetaxel mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[105]
Trabectedin	DMG3Y89	Moderate	Increased metabolism of Nafcillin caused by Trabectedin mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
Armodafinil	DMGB035	Moderate	Increased metabolism of Nafcillin caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[86]
LEE011	DMMX75K	Moderate	Increased metabolism of Nafcillin caused by LEE011 mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
Norethindrone	DMTY169	Moderate	Increased metabolism of Nafcillin caused by Norethindrone mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[47]
Taxol	DMUOT9V	Moderate	Increased metabolism of Nafcillin caused by Taxol mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[106]
Doxorubicin	DMVP5YE	Moderate	Increased metabolism of Nafcillin caused by Doxorubicin mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
Apixaban	DM89JLN	Moderate	Increased metabolism of Nafcillin caused by Apixaban mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[107]
Brilinta	DMBR01X	Moderate	Increased metabolism of Nafcillin caused by Brilinta mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[15]
Cabozantinib	DMIYDT4	Moderate	Increased metabolism of Nafcillin caused by Cabozantinib mediated induction of CYP450 enzyme.	Thyroid cancer [2D10]	[108]
Sirolimus	DMGW1ID	Moderate	Increased metabolism of Nafcillin caused by Sirolimus mediated induction of CYP450 enzyme.	Transplant rejection [NE84]	[12]
Mycophenolate mofetil	DMPQAGE	Moderate	Altered absorption of Nafcillin due to GI flora changes caused by Mycophenolate mofetil.	Transplant rejection [NE84]	[39]
Tacrolimus	DMZ7XNQ	Moderate	Increased metabolism of Nafcillin caused by Tacrolimus mediated induction of CYP450 enzyme.	Transplant rejection [NE84]	[12]
Saxagliptin	DMGXENV	Moderate	Increased metabolism of Nafcillin caused by Saxagliptin mediated induction of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[109]
Linagliptin	DMWFJTR	Moderate	Increased metabolism of Nafcillin caused by Linagliptin mediated induction of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[110]
Elagolix	DMB2C0E	Moderate	Accelerated clearance of Nafcillin due to the transporter induction by Elagolix.	Uterine fibroid [2E86]	[111]
Amiodarone	DMUTEX3	Major	Increased metabolism of Nafcillin caused by Amiodarone mediated induction of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[112]
-----------


⏷ Show the Full List of 160 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Hydrochloric acid	E00015	313	Acidulant
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Dextrose monohydrate	E00538	22814120	Binding agent; Diluent; Flavoring agent; Tonicity agent
Sodium citrate dihydrate	E00369	71474	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Nafcillin 2g/100ml solution	2g/100ml	Solution	Intravenous
Nafcillin 1g powder	1g	Powder	Intravenous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062527.
2	Nafcillin FDA Label
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Sep;162(3):705-10.
7	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
8	Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic antibiotics. Toxicol In Vitro. 2019 Aug;58:51-59. doi: 10.1016/j.tiv.2019.03.015. Epub 2019 Mar 12.
9	A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97.
10	Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
11	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
12	Cerner Multum, Inc. "Australian Product Information.".
13	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
14	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
15	Canadian Pharmacists Association.
16	Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
17	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
19	Product Information. Procardia (nifedipine). Pfizer US Pharmaceuticals, New York, NY.
20	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
21	Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
22	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
23	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
24	Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
25	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
26	Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
27	Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
28	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
29	Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
30	Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
31	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32	Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
33	Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
34	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
35	Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
36	Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
37	Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
38	Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
39	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
40	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
41	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
42	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
43	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
44	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
45	Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
46	Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
47	Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
48	Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
49	Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
50	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
51	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
52	Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
53	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
54	Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
55	Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416]
56	Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
57	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
58	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
59	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
60	Allen MB, Fitzpatrick RW, Barratt A, Cole RB "The use of probenecid to increase the serum amoxycillin levels in patients with bronchiectasis." Respir Med 84 (1990): 143-6. [PMID: 2371437]
61	Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
62	Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
63	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
64	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
65	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
66	Cerner Multum, Inc. "Canadian Product Information.".
67	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
68	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
69	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
70	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
71	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
72	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
73	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
74	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
75	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
76	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
77	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
78	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
79	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
80	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
81	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
82	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
83	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
84	Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
85	Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
86	Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
87	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
88	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
89	Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
90	Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
91	Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
92	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
93	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
94	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
95	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
96	Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
97	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
98	Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
99	Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
100	Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
101	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
102	Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
103	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
104	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
105	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
106	Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
107	Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
108	Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
109	Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
110	Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
111	Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
112	Product Information. Cordarone (amiodarone). Wyeth-Ayerst Laboratories, Philadelphia, PA.